PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-100.00%
Revenue decline while TRAW shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
-100.00%
Both companies reducing costs. Martin Whitman would check industry efficiency trends.
100.00%
Gross profit growth exceeding 1.5x TRAW's 1.92%. David Dodd would verify competitive advantages.
100.00%
Margin expansion exceeding 1.5x TRAW's 1.92%. David Dodd would verify competitive advantages.
7.04%
Similar R&D growth to TRAW's 8.25%. Walter Schloss would investigate industry innovation requirements.
-5.63%
G&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.59%
Operating expenses growth less than half of TRAW's 7.03%. David Dodd would verify sustainability.
2.59%
Total costs growth less than half of TRAW's 6.96%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
13.04%
D&A growth while TRAW reduces D&A. John Neff would investigate differences.
-2.44%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-15.06%
Other expenses reduction while TRAW shows 15.29% growth. Joel Greenblatt would examine advantage.
-3.66%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense change of 100.00% while TRAW maintains burden. Bruce Berkowitz would investigate strategy.
-10.34%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-10.26%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-10.26%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
0.08%
Share count reduction below 50% of TRAW's 0.16%. Michael Burry would check for concerns.
0.08%
Diluted share reduction below 50% of TRAW's 0.16%. Michael Burry would check for concerns.